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 Glomerulonephritis as a disease category 
is one of the leading causes of end-stage 
renal disease in the Western world and is 
associated with increased morbidity and 
mortality. Th e most aggressive form of 
glomerulonephritis with the worst clinical 
outcome is rapidly progressive glomeru-
lonephritis (RPGN). 1 RPGN represents 
a heterogeneous collection of disease enti-
ties that are characterized by immune-
mediated renal damage, consisting of 
a specifi c immune reaction followed by 
an eff ector phase of infl ammation. Th is 
pathophysiological concept is the current 
rationale for unspecifi c immunosuppres-
sive therapy with corticosteroids and cyto-
toxic agents; 1 however, the missing 
specifi city of these therapeutic regimes 
and frequently disabling side eff ects are 
the main reasons for the urgent need to 
develop new and more specifi c individual 
therapeutic strategies. In recent years, very 
few innovative induction therapies for 
RPGN have been established in clinical 
practice; these include mycophenolate 
mofetil for lupus nephritis 2 and, very 
recently, rituximab for ANCA-associated 
glomerulonephritis. 3 
 Green tea has been considered a healthy 
beverage since the beginning of its his-
tory, used in traditional Chinese medicine 
as a treatment for various disease condi-
tions, and to prolong life in general. 4 More 
recent investigations on green tea extracts, 
and more specifi cally the green tea com-
ponent (  −  )-epigallocatechin-3-gallate 
(EGCG), have suggested that these com-
pounds mediate protection from prostate 
and breast cancer, as well as cardiovascu-
lar disease. 5 However,  in vivo evidence to 
support their benefi cial eff ect in immune-
mediated diseases is limited. In experi-
mental models of multiple sclerosis 6 and 
Sj ö gren ’ s syndrome, 7 application of EGCG 
has been shown to reduce the oxidative 
stress response and production of infl am-
matory mediators, resulting in ameliora-
tion of inflammation and improved 
outcome. With respect to renal disease, 
the indisputable ability of this compound 
to protect from oxidative stress has so far 
been applied only to models of kidney 
injury, such as cisplatin-induced nephro-
toxicity 8 and diabetic nephropathy. 9 
 Th us, the identifi cation of new molecular 
targets that may be exploited for therapeu-
tic intervention in crescentic glomerulone-
phritis is a priority in nephrology, with 
emphasis on minimizing the side eff ects 
associated with drug toxicity and immuno-
suppression. Most of the research in this 
fi eld relies on animal models of crescentic 
glomerulonephritis, of which nephrotoxic 
nephritis (NTN) is by far the best charac-
terized. 10 In mice, NTN is induced by 
injection of a heterologous antibody raised 
in sheep or rabbits that binds to the murine 
glomerular basement membrane; this 
induces a xenogenic immune response, 
resulting in immune-mediated glomerular 
damage, crescent formation, and tubu-
lointerstitial leukocyte infi ltration, a patho-
logy that closely resembles human cres centic 
glomerulonephritis. 10 
 Peng and colleagues 11 (this issue) now 
introduce the green tea component EGCG 
as a potential therapeutic compound for 
immune-mediated glomerulonephritis. 
Using the murine NTN model (here 
named murine anti-GBM glomerulo-
nephritis), they show that oral administra-
tion of EGCG ameliorates the clinical 
course of the nephritis. Continuous treat-
ment with EGCG, started 2 days before 
induction of NTN, substantially reduced 
crescent formation, proteinuria, and loss 
of renal function at day 15. Th is improved 
clinical outcome was accompanied by less 
glomerular and tubulointerstitial infi ltra-
tion of macrophages and T cells. The 
authors convincingly demonstrate that 
EGCG therapy ameliorates the oxidative 
stress response that contributes to the 
development of immune-mediated kidney 
injury in nephritic mice. Th e increased 
levels of markers for oxidative stress 
detected in kidney tissue and urine of 
vehicle-treated animals with NTN were 
found to be normal in the EGCG-treated 
group. In further experiments, the authors 
analyzed various enzymes involved in the 
metabolism of reactive oxygen species 
(ROS). In the infl amed kidneys of mice 
with NTN, they found a pattern consistent 
with increased ROS generation along with 
a reduced capacity for ROS degradation. 
Th is deleterious shift  in renal ROS metabo-
lism was counteracted by EGCG therapy. 
In line with these data, other targets that 
are supposedly downstream of the oxida-
tive response were also downregulated in 
the therapeutic group. Increased levels of 
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myeloperoxidase and inducible nitric 
oxide synthase that generate highly cyto-
toxic hypochloric acid and nitric oxide 
metabolites, respectively, were reversed 
by EGCG. Furthermore, activity of the 
central infl ammatory transcription factor 
nuclear factor-  B and the chemoattract-
ant osteopontin was inhibited, providing 
a possible explanation for the reduced 
leukocyte recruitment to the kidney that 
is observed under EGCG therapy. 
 The mechanisms by which EGCG 
administration is presumed to mediate its 
anti-inflammatory effect in immune-
mediated glomerulonephritis are summa-
rized in  Figure 1 . 
 In a second set of experimental mice, 
the authors identify the anti-infl amma-
tory transcription factor peroxisome 
proliferator-activated receptor   (PPAR  ) 
as another potential target of the pluripo-
tent green tea compound. Th e PPAR  
level, found to be markedly downregu-
lated in the kidneys of vehicle-treated 
nephritic mice, was restored by EGCG 
treatment, suggesting that PPAR  activa-
tion might be crucial for its benefi cial 
eff ects. To underline the importance of 
PPAR  for EGCG-mediated protection, 
the authors applied a PPAR  antagonist 
together with EGCG to mice with NTN. 
In line with the hypothesis, concomitant 
treatment almost completely abrogated 
the beneficial effects of the EGCG 
therapy in terms of kidney function and 
histo pathological injury. 
 As in many therapeutic studies based 
on animal models, the data presented 
so far are hampered by diff erences in the 
disease course; whereas the mouse model 
requires a pretreatment episode prior to 
the induction of the disease, human 
autoimmune diseases develop chronically, 
and patients commonly have a long 
history of disease at the time of diagnosis. 
To provide further evidence for the poten-
tial benefits of EGCG as a therapeutic 
compound for human RPGN, the authors 
performed another set of experiments in 
which they initiated EGCG therapy aft er 
full-blown nephritis had developed. In 
these experiments they showed that treat-
ment with EGCG from day 7 aft er induc-
tion of NTN to day 28 was also able to 
protect from renal tissue injury and loss 
of renal function. Perhaps most impor-
tantly, the delayed treatment reduced the 
lethality from more than 40 % to 10 % . 
 In summary, the study of Peng and col-
leagues 11 provides the fi rst experimental 
evidence that green tea extracts are of 
therapeutic value in the treatment of a 
mouse model of RPGN, and hopefully in 
humans in the future. This treatment 
strategy could be particularly attractive as 
green tea extracts have been shown to 
modulate the infl ammatory cascade by 
multiple mechanisms, and are believed to 
have a favorable safety profi le. 12 However, 
future studies to evaluate therapeutic 
EGCG application in humans are needed 
to investigate whether this innovative 
approach can be translated to treatment 
of patients with glomerulonephritis in 
clinical practice. 
 DISCLOSURE 
 The author declared no competing interests. 
 ACKNOWLEDGMENTS 
 I thank U. Panzer, O.M. Steinmetz, and C. 
Wiggins for critically reading the manuscript. 
I am supported by the Klinische 
Forschergruppe 228 grant (together 
with U. Panzer; PA 754 / 7-1) and by a research 
fellowship (TU 316 / 1-1), both from the 
Deutsche Forschungsgemeinschaft. 
 REFERENCES 
 1 .  Couser  WG .  Glomerulonephritis .  Lancet  1999 ;  353 : 
 1509 – 1515 . 
 2 .  Ginzler  EM ,  Dooley  MA ,  Aranow  C  et al. 
 Mycophenolate mofetil or intravenous 
cyclophosphamide for lupus nephritis .  N Engl J 
Med  2005 ;  353 :  2219 – 2228 . 
 3 .  Jones  RB ,  Tervaert  JW ,  Hauser  T  et al.  Rituximab 
versus cyclophosphamide in ANCA-associated 
renal vasculitis .  N Engl J Med  2010 ;  363 :  211 – 220 . 
 4 .  Cabrera  C ,  Artacho  R ,  Gimenez  R .  Beneficial effects 
of green tea: a review .  J Am Coll Nutr  2006 ;  25 : 
 79 – 99 . 
 5 .  Clement  Y .  Can green tea do that? A literature 
review of the clinical evidence .  Prev Med  2009 ;  49 : 
 83 – 87 . 
 6 .  Aktas  O ,  Prozorovski  T ,  Smorodchenko  A 
 et al.  Green tea epigallocatechin-3-gallate 
mediates T cellular NF-kappa B inhibition 
and exerts neuroprotection in autoimmune 
encephalomyelitis .  J Immunol  2004 ;  173 : 
 5794 – 5800 . 
 7 .  Hsu  SD ,  Dickinson  DP ,  Qin  H  et al.  Green tea 
polyphenols reduce autoimmune symptoms in 
a murine model for human Sjogren’s syndrome 
and protect human salivary acinar cells from 
TNF-alpha-induced cytotoxicity .  Autoimmunity 
 2007 ;  40 :  138 – 147 . 
 8 .  Sahin  K ,  Tuzcu  M ,  Gencoglu  H  et al. 
 Epigallocatechin-3-gallate activates Nrf2/
HO-1 signaling pathway in cisplatin-induced 
nephrotoxicity in rats .  Life Sci  2010 ;  87 :  240 – 245 . 
 9 .  Yamabe  N ,  Yokozawa  T ,  Oya  T  et al.  Therapeutic 
potential of (  −  )-epigallocatechin 3- O -gallate on 
renal damage in diabetic nephropathy model rats . 
 J Pharmacol Exp Ther  2006 ;  319 :  228 – 236 . 
 10 .  Anders  H ,  Schl ö ndorff  D .  Murine models of renal 
disease: possibilities and problems in studies 
using mutant mice .  Exp Nephrol  2000 ;  8 : 
 181 – 193 . 
 11 .  Peng  A ,  Ye  T ,  Rakheja  D  et al.  The green tea 
polyphenol (  −  )-epigallocatechin-3-gallate 
ameliorates experimental immune-mediated 
glomerulonephritis .  Kidney Int  2011 ;  80 : 
 601 – 611 . 
 12 .  Chan  PC ,  Ramot  Y ,  Malarkey  DE  et al.  Fourteen-
week toxicity study of green tea extract in rats 
and mice .  Toxicol Pathol  2010 ;  38 :  1070 – 1084 . 
Catalase
GPx
SOD-1
EGCG
ROS
degradation
ROS NF-κB iNOS MPO
Inflammatory
mediators
NO
metabolites
Hypochloric
acid
OPN PPARγ
Immune-cell infiltration and renal tissue damage
Stimulation
Inhibition
 Figure 1  |  Proposed mechanisms for the anti-inflammatory effects of (  −  )-epigallocatechin-
3-gallate in immune-mediated glomerulonephritis. (  −  )-Epigallocatechin-3-gallate (EGCG) 
attenuates immune-mediated kidney injury by acting on multiple targets in the inflammatory 
cascade. Inhibiting the generation of reactive oxygen species (ROS) and facilitating their 
degradation are probably among the most important mechanisms. Furthermore, EGCG has been 
shown to upregulate renal expression of the anti-inflammatory transcription factor peroxisome 
proliferator-activated receptor   (PPAR  ). GPx, glutathione peroxidase; iNOS, inducible nitric oxide 
synthase; MPO, myeloperoxidase; NF-  B, nuclear factor-  B; NO, nitric oxide; OPN, osteopontin; 
SOD-1, superoxide dismutase 1. 
